More than 81,000 individuals are diagnosed with bladder cancer in the United States every year, of whom 75% have non-muscle invasive disease.1,2 Unfortunately, half these cases recur despite transurethral resection of bladder tumor (TURBT), and from 5% to 25% of repeated recurrences progress to muscle-invasive disease.3,4,5
Centers of Excellence
The Latest Research on Bladder Cancer
In 2019, more than 80,000 Americans will be diagnosed with bladder cancer, and more than 17,000 patients will die from it.1 Whether it’s the neighbor we greet each morning, the aunt we joke with at family reunions, or even the face we see each day in the mirror, bladder cancer affects us all. It is a complex, challenging disease, and its prognosis has improved only recently after three decades of relative stagnancy.
Ashish Kamat, MD, MBBS, is a Professor of Urology and Wayne B. Duddleston Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. Dr. Kamat serves as; President of International Bladder Cancer Group, Co-President of International Bladder Cancer Network, and Associate Cancer Center Director. Dr. Kamat served as the Program Director, of the MD Anderson Urologic Oncology Fellowship from 2005-2016.